Clinical Trials Browser

OTHER × eliglustat × 90 days × Clear all

NCT06558773 2026-02-11

GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07138547 2026-01-02

GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma

Phase 1/2 Recruiting

Lymphoma